Literature DB >> 28886003

Functional precision cancer medicine-moving beyond pure genomics.

Anthony Letai1.   

Abstract

The essential job of precision medicine is to match the right drugs to the right patients. In cancer, precision medicine has been nearly synonymous with genomics. However, sobering recent studies have generally shown that most patients with cancer who receive genomic testing do not benefit from a genomic precision medicine strategy. Although some call the entire project of precision cancer medicine into question, I suggest instead that the tools employed must be broadened. Instead of relying exclusively on big data measurements of initial conditions, we should also acquire highly actionable functional information by perturbing-for example, with cancer therapies-viable primary tumor cells from patients with cancer.

Entities:  

Mesh:

Year:  2017        PMID: 28886003     DOI: 10.1038/nm.4389

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  69 in total

1.  Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737.

Authors:  Victoria Del Gaizo Moore; Jennifer R Brown; Michael Certo; Tara M Love; Carl D Novina; Anthony Letai
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

2.  BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents.

Authors:  Jing Deng; Nicole Carlson; Kunihiko Takeyama; Paola Dal Cin; Margaret Shipp; Anthony Letai
Journal:  Cancer Cell       Date:  2007-08       Impact factor: 31.743

3.  Precision oncology: a strategy we were not ready to deploy.

Authors:  Tito Fojo
Journal:  Semin Oncol       Date:  2016-01-28       Impact factor: 4.929

4.  iBH3: simple, fixable BH3 profiling to determine apoptotic priming in primary tissue by flow cytometry.

Authors:  Jeremy Ryan; Joan Montero; James Rocco; Anthony Letai
Journal:  Biol Chem       Date:  2016-07-01       Impact factor: 3.915

5.  Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.

Authors:  Pei-Ling Chen; Whijae Roh; Alexandre Reuben; Zachary A Cooper; Christine N Spencer; Peter A Prieto; John P Miller; Roland L Bassett; Vancheswaran Gopalakrishnan; Khalida Wani; Mariana Petaccia De Macedo; Jacob L Austin-Breneman; Hong Jiang; Qing Chang; Sangeetha M Reddy; Wei-Shen Chen; Michael T Tetzlaff; Russell J Broaddus; Michael A Davies; Jeffrey E Gershenwald; Lauren Haydu; Alexander J Lazar; Sapna P Patel; Patrick Hwu; Wen-Jen Hwu; Adi Diab; Isabella C Glitza; Scott E Woodman; Luis M Vence; Ignacio I Wistuba; Rodabe N Amaria; Lawrence N Kwong; Victor Prieto; R Eric Davis; Wencai Ma; Willem W Overwijk; Arlene H Sharpe; Jianhua Hu; P Andrew Futreal; Jorge Blando; Padmanee Sharma; James P Allison; Lynda Chin; Jennifer A Wargo
Journal:  Cancer Discov       Date:  2016-06-14       Impact factor: 39.397

6.  Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML.

Authors:  Thanh-Trang Vo; Jeremy Ryan; Ruben Carrasco; Donna Neuberg; Derrick J Rossi; Richard M Stone; Daniel J Deangelo; Mark G Frattini; Anthony Letai
Journal:  Cell       Date:  2012-10-12       Impact factor: 41.582

Review 7.  Mitochondria-Judges and Executioners of Cell Death Sentences.

Authors:  Patrick D Bhola; Anthony Letai
Journal:  Mol Cell       Date:  2016-03-03       Impact factor: 17.970

8.  Prospective cohort study using the breast cancer spheroid model as a predictor for response to neoadjuvant therapy--the SpheroNEO study.

Authors:  Kathrin Halfter; Nina Ditsch; Hans-Christian Kolberg; Holger Fischer; Tanja Hauzenberger; Franz Edler von Koch; Ingo Bauerfeind; Gunter von Minckwitz; Ilona Funke; Alexander Crispin; Barbara Mayer
Journal:  BMC Cancer       Date:  2015-07-15       Impact factor: 4.430

9.  Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine.

Authors:  Eliezer M Van Allen; Nikhil Wagle; Petar Stojanov; Danielle L Perrin; Kristian Cibulskis; Sara Marlow; Judit Jane-Valbuena; Dennis C Friedrich; Gregory Kryukov; Scott L Carter; Aaron McKenna; Andrey Sivachenko; Mara Rosenberg; Adam Kiezun; Douglas Voet; Michael Lawrence; Lee T Lichtenstein; Jeff G Gentry; Franklin W Huang; Jennifer Fostel; Deborah Farlow; David Barbie; Leena Gandhi; Eric S Lander; Stacy W Gray; Steven Joffe; Pasi Janne; Judy Garber; Laura MacConaill; Neal Lindeman; Barrett Rollins; Philip Kantoff; Sheila A Fisher; Stacey Gabriel; Gad Getz; Levi A Garraway
Journal:  Nat Med       Date:  2014-05-18       Impact factor: 53.440

10.  Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.

Authors:  Anas Younes; Armando Santoro; Margaret Shipp; Pier Luigi Zinzani; John M Timmerman; Stephen Ansell; Philippe Armand; Michelle Fanale; Voravit Ratanatharathorn; John Kuruvilla; Jonathon B Cohen; Graham Collins; Kerry J Savage; Marek Trneny; Kazunobu Kato; Benedetto Farsaci; Susan M Parker; Scott Rodig; Margaretha G M Roemer; Azra H Ligon; Andreas Engert
Journal:  Lancet Oncol       Date:  2016-07-20       Impact factor: 41.316

View more
  100 in total

1.  DDX3X Suppresses the Susceptibility of Hindbrain Lineages to Medulloblastoma.

Authors:  Deanna M Patmore; Amir Jassim; Erica Nathan; Reuben J Gilbertson; Daniel Tahan; Nadin Hoffmann; Yiai Tong; Kyle S Smith; Thirumala-Devi Kanneganti; Hiromichi Suzuki; Michael D Taylor; Paul Northcott; Richard J Gilbertson
Journal:  Dev Cell       Date:  2020-06-17       Impact factor: 12.270

Review 2.  Human Colon Organoids and Other Laboratory Strategies to Enhance Patient Treatment Selection.

Authors:  Katherine A Johnson; Rebecca A DeStefanis; Philip B Emmerich; Patrick T Grogan; Jeremy D Kratz; Sarbjeet K Makkar; Linda Clipson; Dustin A Deming
Journal:  Curr Treat Options Oncol       Date:  2020-04-23

3.  Multiplexed drug testing of tumor slices using a microfluidic platform.

Authors:  A Folch; R C Rostomily; L F Horowitz; A D Rodriguez; Z Dereli-Korkut; R Lin; K Castro; A M Mikheev; R J Monnat
Journal:  NPJ Precis Oncol       Date:  2020-05-19

Review 4.  Promises, promises, and precision medicine.

Authors:  Michael J Joyner; Nigel Paneth
Journal:  J Clin Invest       Date:  2019-01-28       Impact factor: 14.808

Review 5.  New Treatment Options for Acute Myeloid Leukemia in 2019.

Authors:  Marco Cerrano; Raphael Itzykson
Journal:  Curr Oncol Rep       Date:  2019-02-04       Impact factor: 5.075

Review 6.  Protein biomarkers for subtyping breast cancer and implications for future research.

Authors:  Claudius Mueller; Amanda Haymond; Justin B Davis; Alexa Williams; Virginia Espina
Journal:  Expert Rev Proteomics       Date:  2018-01-03       Impact factor: 3.940

Review 7.  Clinical potential of mass spectrometry-based proteogenomics.

Authors:  Bing Zhang; Jeffrey R Whiteaker; Andrew N Hoofnagle; Geoffrey S Baird; Karin D Rodland; Amanda G Paulovich
Journal:  Nat Rev Clin Oncol       Date:  2019-04       Impact factor: 66.675

Review 8.  Personalized Cancer Models for Target Discovery and Precision Medicine.

Authors:  Carla Grandori; Christopher J Kemp
Journal:  Trends Cancer       Date:  2018-08-08

Review 9.  Targeting minimal residual disease: a path to cure?

Authors:  Marlise R Luskin; Mark A Murakami; Scott R Manalis; David M Weinstock
Journal:  Nat Rev Cancer       Date:  2018-01-29       Impact factor: 60.716

10.  An in vitro model of tumor heterogeneity resolves genetic, epigenetic, and stochastic sources of cell state variability.

Authors:  Corey E Hayford; Darren R Tyson; C Jack Robbins; Peter L Frick; Vito Quaranta; Leonard A Harris
Journal:  PLoS Biol       Date:  2021-06-01       Impact factor: 8.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.